CL2011000073A1 - Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar. - Google Patents

Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar.

Info

Publication number
CL2011000073A1
CL2011000073A1 CL2011000073A CL2011000073A CL2011000073A1 CL 2011000073 A1 CL2011000073 A1 CL 2011000073A1 CL 2011000073 A CL2011000073 A CL 2011000073A CL 2011000073 A CL2011000073 A CL 2011000073A CL 2011000073 A1 CL2011000073 A1 CL 2011000073A1
Authority
CL
Chile
Prior art keywords
pyrimidyl
amino
treatment
pharmaceutical composition
fibrosis
Prior art date
Application number
CL2011000073A
Other languages
English (en)
Inventor
Elisabeth Manley Paul W Buchdunger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39765085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011000073A1 publication Critical patent/CL2011000073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de derivados de pirimidil-amino-benzamida; composición farmacéutica de dichos compuestos; combinación farmacéutica; y su uso en el tratamiento de fibrosis hepática y fibrosis pulmonar.
CL2011000073A 2008-07-14 2011-01-13 Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar. CL2011000073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08160366 2008-07-14

Publications (1)

Publication Number Publication Date
CL2011000073A1 true CL2011000073A1 (es) 2011-07-15

Family

ID=39765085

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000073A CL2011000073A1 (es) 2008-07-14 2011-01-13 Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar.

Country Status (17)

Country Link
US (2) US20110124670A1 (es)
EP (1) EP2300014A1 (es)
JP (1) JP2011528015A (es)
KR (1) KR20110051194A (es)
CN (1) CN102099039A (es)
AU (1) AU2009272814A1 (es)
BR (1) BRPI0915905A2 (es)
CA (1) CA2730225A1 (es)
CL (1) CL2011000073A1 (es)
IL (1) IL210290A0 (es)
MA (1) MA33166B1 (es)
MX (1) MX2011000511A (es)
NZ (1) NZ590177A (es)
RU (1) RU2011105059A (es)
TW (1) TW201006823A (es)
WO (1) WO2010007034A1 (es)
ZA (1) ZA201009153B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098993A1 (en) * 2011-07-28 2015-04-09 Shireen Vali Compositions, process of preparation of said compositions and method of treating inflammatory diseases
BR112014026305A2 (pt) * 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
BR112014026266A2 (pt) * 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
CN103965195B (zh) * 2013-02-01 2016-09-28 中国科学院广州生物医药与健康研究院 用于盘状结构域受体小分子抑制剂的化合物及其应用
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CN106282033A (zh) * 2016-08-15 2017-01-04 郑毅男 一株新青霉菌及其代谢产物安他拟酸a
KR102914830B1 (ko) * 2019-10-15 2026-01-19 재단법인 한국파스퇴르연구소 2-메톡시에스트라디올 유도체 및 이들의 의약 용도
CN115010720B (zh) * 2022-06-02 2023-08-11 中国科学院昆明植物研究所 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
US20050124624A1 (en) * 2002-03-15 2005-06-09 Gilbert Richard E. 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases
AU2005294320A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
KR20090055595A (ko) * 2006-08-25 2009-06-02 노파르티스 아게 알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
EA200900812A1 (ru) * 2006-12-18 2009-12-30 Новартис Аг Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
CN101578272A (zh) * 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途

Also Published As

Publication number Publication date
NZ590177A (en) 2012-12-21
CN102099039A (zh) 2011-06-15
WO2010007034A1 (en) 2010-01-21
MX2011000511A (es) 2011-02-24
EP2300014A1 (en) 2011-03-30
CA2730225A1 (en) 2010-01-21
TW201006823A (en) 2010-02-16
ZA201009153B (en) 2011-11-30
KR20110051194A (ko) 2011-05-17
RU2011105059A (ru) 2012-08-20
MA33166B1 (fr) 2012-04-02
BRPI0915905A2 (pt) 2018-02-20
US20110124670A1 (en) 2011-05-26
AU2009272814A1 (en) 2010-01-21
IL210290A0 (en) 2011-03-31
JP2011528015A (ja) 2011-11-10
US20130267549A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2013001655A1 (es) Compuestos bifenilicos sustituidos; composicion farmaceutica; y uso en el tratamiento o prevencion de fibrosis pulmonar, renal, hepatica o cutanea.
BRPI0814769A2 (pt) Composição sinérgica compreendendo substâncias aromatizantes e ácidos orgânicos e uso da mesma
BRPI0911333A2 (pt) composições de limpeza que incorporam solventes verdes e métodos de uso.
EA200802008A1 (ru) Фармацевтические композиции
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI1005292A2 (pt) composição de decapagem e uso da composição
CR10847A (es) Compuesto heteromonociclico y uso del mismo
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
EA200901597A1 (ru) Гербицидно активные бициклические 1,3-дионы
EP2252671A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND DIMETHOXYMETHANE
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
EP2252669A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND METHYL ACETATE
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica